Saccharide conjugates

US10046068B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10046068-B2
Application numberUS-201414776578-A
CountryUS
Kind codeB2
Filing dateMar 14, 2014
Priority dateMar 15, 2013
Publication dateAug 14, 2018
Grant dateAug 14, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of formula (I): [A-R 6 n R 7 —R 8   (I) or a pharmaceutically acceptable salt thereof, wherein A is: R 1 is selected from the group consisting of H, OH, SH, NH 2 , OR 4 , OC(O)R 4 , OC(O)NHR 4 , OC(O)NR 4 R 5 , OC(S)NHR 4 , OC(S)NR 4 R 5 , SC(O)NHR 4 , SC(O)NR 4 R 5 , NHC(O)NHR 4 , NHC(O)NR 4 R 5 , NHC(S)NHR 4 , NHC(S)NR 4 R 5 , NHC(N)NHR 4 , NHC(N)NR 4 R 5 , OCH 2 C(O)NHR 4 , OCH 2 C(O)NR 4 R 5 , OCH 2 C(S)NHR 4 , OCH 2 C(S)NR 4 R 5 , SCH 2 C(O)NHR 4 , SCH 2 C(O)NR 4 R 5 , NHCH 2 C(O)NHR 4 , NHCH 2 C(O)NR 4 R 5 , NHCH 2 C(S)NHR 4 and NHCH 2 C(S)NR 4 R 5 ; each R 4 is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl; each R 5 is selected from the group consisting of C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl; R 2 is selected from the group consisting of H, OH, SH, NH 2 , OR 4 , OC(O)R 4 , OC(O)NHR 4 , OC(O)NR 4 R 5 , OC(S)NHR 4 , OC(S)NR 4 R 5 , SC(O)NHR 4 , SC(O)NR 4 R 5 , NHC(O)NHR 4 , NHC(O)NR 4 R 5 , NHC(S)NHR 4 , NHC(S)NR 4 R 5 , NHC(N)NHR 4 , NHC(N)NR 4 R 5 , OCH 2 C(O)NHR 4 , OCH 2 C(O)NR 4 R 5 , OCH 2 C(S)NHR 4 , OCH 2 C(S)NR 4 R 5 , SCH 2 C(O)NHR 4 , SCH 2 C(O)NR 4 R 5 , NHCH 2 C(O)NHR 4 , NHCH 2 C(O)NR 4 R 5 , NHCH 2 C(S)NHR 4 and NHCH 2 C(S)NR 4 R 5 ; R 3 is selected from the group consisting of H, OH, SH, NH 2 , OR 4 , OC(O)R 4 , OC(O)NHR 4 , OC(O)NR 4 R 5 , OC(S)NHR 4 , OC(S)NR 4 R 5 , SC(O)NHR 4 , SC(O)NR 4 R 5 , NHC(O)NHR 4 , NHC(O)NR 4 R 5 , NHC(S)NHR 4 , NHC(S)NR 4 R 5 , NHC(N)NHR 4 , NHC(N)NR 4 R 5 , OCH 2 C(O)NHR 4 , OCH 2 C(O)NR 4 R 5 , OCH 2 C(S)NHR 4 , OCH 2 C(S)NR 4 R 5 , SCH 2 C(O)NHR 4 , SCH 2 C(O)NR 4 R 5 , NHCH 2 C(O)NHR 4 , NHCH 2 C(O)NR 4 R 5 , NHCH 2 C(S)NHR 4 and NHCH 2 C(S)NR 4 R 5 ; R′ is selected from the group consisting of H, OH and NHR 4 ; R 6 is a first linker; n is an integer selected from 1 to 3; R 7 is absent or a second linker, provided that when n is 1, R 7 is absent; and R 8 is Cy5**. 2. The compound according to claim 1 , wherein A is selected from the group consisting of: 3. The compound according to claim 1 , wherein the first linker is X-(L 1 -Y) m -L 2 -Z, wherein X is CH 2 or O; L 1 is C 2 -C 6 alkyl; Y is O, S, or NR y , wherein R y is hydrogen or C 1 -C 6 alkyl; m is an integer selected from 1 to 10; L 2 is C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, aryl, heteroaryl, heterocyclyl, C 3 -C 5 cycloalkyl; and Z is absent, O, NR x , S, C(O), S(O), S(O) 2 , OC(O), N(R x )C(O), N(R x )S(O), N(R x )S(O) 2 , C(O)O, C(O)N(R x ), S(O)N(R x ), S(O) 2 N(R x ), OC(O)O, OC(O)N(R x ), N(R x )C(O)O, N(R x )C(O)N(R x ), or N(R x )S(O) 2 N(R x ), wherein each R x is independently hydrogen or C 1 -C 6 alkyl. 4. The compound of claim 3 , wherein the first linker is O—(CH 2 CH 2 —O) m —CH 2 CH 2 —Z, wherein Z is O, N(H), or S and m is an integer selected from 1 to 20 or the first linker is O—(CH 2 CH 2 —O) m —CH 2 CH 2 —Z, wherein Z is C(O) or S(O) 2 and m is an integer selected from 1 to 20. 5. The compound according to claim 1 , wherein the second linker is (B-L 3 ) p -D-E-L 4 -F, wherein B is bond, O, NR x , S, C(O), S(O), S(O) 2 , OC(O), N(R x )C(O), N(R x )S(O), N(R x )S(O) 2 , C(O)O, C(O)N(R x ), S(O)N(R x ), S(O) 2 N(R x ), OC(O)O, OC(O)N(R x ), N(R x )C(O)O, N(R x )C(O)N(R x ), or N(R x )S(O) 2 N(R x ); L 3 is C 2 -C 6 alkyl; p is 2 or 3; D is CH when p is 2 and D is C when p is 3; E is a bond, O, NR x , S, C(O), S(O), S(O) 2 , OC(O), N(R x )C(O), N(R x )S(O), N(R x )S(O) 2 , C(O)O, C(O)N(R x ), S(O)N(R x ), S(O) 2 N(R x ), OC(O)O, OC(O)N(R x ), N(R x )C(O)O, N(R x )C(O)N(R x ), or N(R x )S(O) 2 N(R x ); L 4 is C 2 -C 6 alkyl; and F is a bond, O, NR x , S, C(O), S(O), S(O) 2 , OC(O), N(R x )C(O), N(R x )S(O), N(R x )S(O) 2 , C(O)O, C(O)N(R x ), S(O)N(R x ), S(O) 2 N(R x ), OC(O)O, OC(O)N(R X ), N(R X )C(O)O, N(R x )C(O)N(R x ), or N(R x )S(O) 2 N(R x ), wherein each R x is independently hydrogen or C 1 -C 6 alkyl. 6. The compound according to claim 1 , wherein R 1 is selected from the group consisting of H, OH, OR 4 , OC(O)R 4 , NHC(N)NHR 4 , NHC(N)NR 4 R 5 , OCONHR 4 , and OCONR 4 R 5 . 7. The compound according to claim 1 , wherein R 2 is selected from the group consisting of H, OH, OR 4 , OC(O)R 4 , NHC(N)NHR 4 , NHC(N)NR 4 R 5 , OCONHR 4 , OCONR 4 R 5 , OCSNHR 4 , NHCONHR 4 , OCH 2 CONHR 4 , and OCH 2 CONR 4 R 5 . 8. The compound according to claim 1 , wherein R 3 is selected from the group consisting of OH, OR 4 , OC(O)R 4 , NHC(N)NHR 4 , NHC(N)NR 4 R 5 , and OCONHR 4 . 9. The compound according to claim 1 , wherein R′ is H or OH. 10. The compound according to claim 1 , wherein each R 4 is selected from the group consisting of H, methyl and ethyl. 11. The compound according to claim 1 , wherein each R 5 is selected from the group consisting of methyl, ethyl, and isobutyl. 12. A compound selected from the group consisting of:

Assignees

Inventors

Classifications

  • Microbubbles, hollow microspheres, free gas bubbles, gas microspheres · CPC title

  • Heterocyclic compounds (A61K47/558 takes precedence) · CPC title

  • conjugates with a carrier being an organic compounds · CPC title

  • General or multifunctional contrast agents, e.g. chelated agents · CPC title

  • Small organic molecules (oligomers, polymers, dendrimers A61K49/0054) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10046068B2 cover?
This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors.
Who is the assignee on this patent?
Arizona Board Of Regents For And On Behalf Of Arizona State Univ, Univ Arizona State
What technology area does this patent fall under?
Primary CPC classification A61K49/0052. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).